Basic and clinical studies on SY5555 in the urological field

T. Hayashi, Toyohiko Watanabe, T. Takenaka, K. Hata, N. Ono, H. Kumon, H. Ohmori, K. Kondo, T. Ohasi, T. Akaeda, Y. Katayama

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We studied the antibacterial activity and clinical efficacy of SY5555, a new oral penem antibiotic, in the urological field. 1) Antibacterial activity: We determined the MICs of SY5555 against 210 clinically isolated strains of 14 species from urinary tract infections, and compared them with those of cefaclor (CCL), cefixime (CFIX) and ofloxacin (OFLX). Against gram-positive organisms, the overall antibacterial activity of SY5555 was superior to that of other antibiotics. Against gram-negative organisms the activity of SY5555 was almost equivalent to that of other antibiotics. 2) Clinical efficacy: Thirteen patients with acute uncomplicated cystitis (AUC) and 17 patients with chronic complicated urinary tract infections (C-UTI) were treated with SY5555. In 11 cases of AUC, the overall clinical efficacy rate according to the criteria of the Japanese UTI Committee was 100% and all 12 strains were eradicated bacteriologically. In 15 cases of C-UTI, the overall clinical efficacy rate according to the same criteria was 73.3%. Bacteriologically, 16 of 18 strains (88.9%) were eradicated. 3) Side effects: No side effects were observed in 30 cases, and no abnormal laboratory findings were noted in 24 cases.

Original languageEnglish
Pages (from-to)475-484
Number of pages10
JournalChemotherapy
Volume42
Issue numberSUPPL. 1
Publication statusPublished - 1994

Fingerprint

Urinary Tract Infections
Cystitis
meropenem
Anti-Bacterial Agents
Cefixime
Cefaclor
Ofloxacin
SUN 5555
Clinical Studies

Keywords

  • SY5555

ASJC Scopus subject areas

  • Pharmacology

Cite this

Hayashi, T., Watanabe, T., Takenaka, T., Hata, K., Ono, N., Kumon, H., ... Katayama, Y. (1994). Basic and clinical studies on SY5555 in the urological field. Chemotherapy, 42(SUPPL. 1), 475-484.

Basic and clinical studies on SY5555 in the urological field. / Hayashi, T.; Watanabe, Toyohiko; Takenaka, T.; Hata, K.; Ono, N.; Kumon, H.; Ohmori, H.; Kondo, K.; Ohasi, T.; Akaeda, T.; Katayama, Y.

In: Chemotherapy, Vol. 42, No. SUPPL. 1, 1994, p. 475-484.

Research output: Contribution to journalArticle

Hayashi, T, Watanabe, T, Takenaka, T, Hata, K, Ono, N, Kumon, H, Ohmori, H, Kondo, K, Ohasi, T, Akaeda, T & Katayama, Y 1994, 'Basic and clinical studies on SY5555 in the urological field', Chemotherapy, vol. 42, no. SUPPL. 1, pp. 475-484.
Hayashi T, Watanabe T, Takenaka T, Hata K, Ono N, Kumon H et al. Basic and clinical studies on SY5555 in the urological field. Chemotherapy. 1994;42(SUPPL. 1):475-484.
Hayashi, T. ; Watanabe, Toyohiko ; Takenaka, T. ; Hata, K. ; Ono, N. ; Kumon, H. ; Ohmori, H. ; Kondo, K. ; Ohasi, T. ; Akaeda, T. ; Katayama, Y. / Basic and clinical studies on SY5555 in the urological field. In: Chemotherapy. 1994 ; Vol. 42, No. SUPPL. 1. pp. 475-484.
@article{c90917475b3447a484172580d7d92da2,
title = "Basic and clinical studies on SY5555 in the urological field",
abstract = "We studied the antibacterial activity and clinical efficacy of SY5555, a new oral penem antibiotic, in the urological field. 1) Antibacterial activity: We determined the MICs of SY5555 against 210 clinically isolated strains of 14 species from urinary tract infections, and compared them with those of cefaclor (CCL), cefixime (CFIX) and ofloxacin (OFLX). Against gram-positive organisms, the overall antibacterial activity of SY5555 was superior to that of other antibiotics. Against gram-negative organisms the activity of SY5555 was almost equivalent to that of other antibiotics. 2) Clinical efficacy: Thirteen patients with acute uncomplicated cystitis (AUC) and 17 patients with chronic complicated urinary tract infections (C-UTI) were treated with SY5555. In 11 cases of AUC, the overall clinical efficacy rate according to the criteria of the Japanese UTI Committee was 100{\%} and all 12 strains were eradicated bacteriologically. In 15 cases of C-UTI, the overall clinical efficacy rate according to the same criteria was 73.3{\%}. Bacteriologically, 16 of 18 strains (88.9{\%}) were eradicated. 3) Side effects: No side effects were observed in 30 cases, and no abnormal laboratory findings were noted in 24 cases.",
keywords = "SY5555",
author = "T. Hayashi and Toyohiko Watanabe and T. Takenaka and K. Hata and N. Ono and H. Kumon and H. Ohmori and K. Kondo and T. Ohasi and T. Akaeda and Y. Katayama",
year = "1994",
language = "English",
volume = "42",
pages = "475--484",
journal = "Chemotherapy",
issn = "0009-3165",
publisher = "S. Karger AG",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Basic and clinical studies on SY5555 in the urological field

AU - Hayashi, T.

AU - Watanabe, Toyohiko

AU - Takenaka, T.

AU - Hata, K.

AU - Ono, N.

AU - Kumon, H.

AU - Ohmori, H.

AU - Kondo, K.

AU - Ohasi, T.

AU - Akaeda, T.

AU - Katayama, Y.

PY - 1994

Y1 - 1994

N2 - We studied the antibacterial activity and clinical efficacy of SY5555, a new oral penem antibiotic, in the urological field. 1) Antibacterial activity: We determined the MICs of SY5555 against 210 clinically isolated strains of 14 species from urinary tract infections, and compared them with those of cefaclor (CCL), cefixime (CFIX) and ofloxacin (OFLX). Against gram-positive organisms, the overall antibacterial activity of SY5555 was superior to that of other antibiotics. Against gram-negative organisms the activity of SY5555 was almost equivalent to that of other antibiotics. 2) Clinical efficacy: Thirteen patients with acute uncomplicated cystitis (AUC) and 17 patients with chronic complicated urinary tract infections (C-UTI) were treated with SY5555. In 11 cases of AUC, the overall clinical efficacy rate according to the criteria of the Japanese UTI Committee was 100% and all 12 strains were eradicated bacteriologically. In 15 cases of C-UTI, the overall clinical efficacy rate according to the same criteria was 73.3%. Bacteriologically, 16 of 18 strains (88.9%) were eradicated. 3) Side effects: No side effects were observed in 30 cases, and no abnormal laboratory findings were noted in 24 cases.

AB - We studied the antibacterial activity and clinical efficacy of SY5555, a new oral penem antibiotic, in the urological field. 1) Antibacterial activity: We determined the MICs of SY5555 against 210 clinically isolated strains of 14 species from urinary tract infections, and compared them with those of cefaclor (CCL), cefixime (CFIX) and ofloxacin (OFLX). Against gram-positive organisms, the overall antibacterial activity of SY5555 was superior to that of other antibiotics. Against gram-negative organisms the activity of SY5555 was almost equivalent to that of other antibiotics. 2) Clinical efficacy: Thirteen patients with acute uncomplicated cystitis (AUC) and 17 patients with chronic complicated urinary tract infections (C-UTI) were treated with SY5555. In 11 cases of AUC, the overall clinical efficacy rate according to the criteria of the Japanese UTI Committee was 100% and all 12 strains were eradicated bacteriologically. In 15 cases of C-UTI, the overall clinical efficacy rate according to the same criteria was 73.3%. Bacteriologically, 16 of 18 strains (88.9%) were eradicated. 3) Side effects: No side effects were observed in 30 cases, and no abnormal laboratory findings were noted in 24 cases.

KW - SY5555

UR - http://www.scopus.com/inward/record.url?scp=0028264551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028264551&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028264551

VL - 42

SP - 475

EP - 484

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

IS - SUPPL. 1

ER -